preventative treatments

The U.S. government is funding a $375 million effort for a new COVID-19 prevention drug for immunocompromised people, as part of Project NextGen. The federal health department provided the funds to the drug company Shionogi Inc. for a long-acting pre-exposure prophylactic (PreP) called S-892216 that blocks the main protease of SARS-CoV-2.